Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

letrozole

Known as: Letrozol, letrozole [Chemical/Ingredient], Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis- 
A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Previous analyses of the Breast International Group (BIG) 1-98 four-arm study compared initial therapy with letrozole or… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
background In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy — but not tamoxifen therapy of… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
PURPOSE To compare the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamoxifen… Expand
Is this relevant?